Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistMEDVi, LLC was cited for misbranding compounded semaglutide and tirzepatide products offered on its website in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs when it was not, and made misleading claims that the products had the "same active ingredient" as FDA-approved drugs like Wegovy, Ozempic, Mounjaro, and Zepbound—implying FDA approval or evaluation when the compounded products had not been approved. These violations of sections 502(a) and 502(bb) of the FDCA resulted in misbranded drugs being introduced into interstate commerce.